Log in

Relevant bibliographies by topics / REMAP-CAP

Contents

Journal articles

Academic literature on the topic 'REMAP-CAP'

Author: Grafiati

Published: 5 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'REMAP-CAP.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "REMAP-CAP"

1

Aryal, Diptesh, Abi Beane, Arjen M. Dondorp, et al. "Operationalisation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 trials in a low and lower-middle income critical care learning health system." Wellcome Open Research 6 (January 28, 2021): 14. http://dx.doi.org/10.12688/wellcomeopenres.16486.1.

Full text

Abstract:

The Randomized Embedded Multifactorial Adaptive Platform (REMAP-CAP) adapted for COVID-19) trial is a global adaptive platform trial of hospitalised patients with COVID-19. We describe implementation in three countries under the umbrella of the Wellcome supported Low and Middle Income Country (LMIC) critical care network: Collaboration for Research, Implementation and Training in Asia (CCA). The collaboration sought to overcome known barriers to multi centre-clinical trials in resource-limited settings. Methods described focused on six aspects of implementation: i, Strengthening an existing co

APA, Harvard, Vancouver, ISO, and other styles

2

Arabi, Yaseen M., Anthony C. Gordon, Lennie P. G. Derde, et al. "Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial." Intensive Care Medicine 47, no. 8 (2021): 867–86. http://dx.doi.org/10.1007/s00134-021-06448-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Angus, Derek C., Scott Berry, Roger J. Lewis, et al. "The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design." Annals of the American Thoracic Society 17, no. 7 (2020): 879–91. http://dx.doi.org/10.1513/annalsats.202003-192sd.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Klymenko, Valeriia, Haritha Mopuru, Arsalan Alvi, et al. "COVID-19 TREATMENT GUIDELINES FOR HOSPITALIZED PATIENTS AT ST. VINCENT’S MEDICAL CENTER, A LICENSED 473-BED COMMUNITY TEACHING HOSPITAL WITH A LEVEL II TRAUMA CENTER IN THE UNITED STATES." Asthma and allergy 2021, no. 3 (2021): 50–55. http://dx.doi.org/10.31655/2307-3373-2021-3-50-55.

Full text

Abstract:

КЕРІВНИЦТВО З ЛІКУВАННЯ COVID-19 ДЛЯ ГОСПІТАЛІЗОВАНИХ ПАЦІЄНТІВ В ЛІЦЕНЗОВАНОМУ 473-ЛІЖКОВОМУ НАВЧАЛЬНОМУ МЕДИЧНОМУ ЦЕНТРІ СВ. ВІНСЕНТА З ТРАВМАТОЛОГІЧНИМ ЦЕНТРОМ ІІ РІВНЯ В СПОЛУЧЕНИХ ШТАТАХ АМЕРИКИ В. Клименко1 , Х. Мупуру1 , А. Алві1 , М. Морель1 , Н. Дятлова2 , М. Еліас1 , Д. Регелманн1 1 Медичний центр Святого Вінсента, Медична допомога Гартворда, Бріджпорт, СТ (США); 2 Програма Резидентури Внутрішньої Медицини Чиказької Медичної Школи в Північно-Західній Лікарні Мак-Генрі, Мак-Генрі, Іллінойс, США Резюме. Мета публікації — обговорення власного досвіду для підвищення ефективності медичної

APA, Harvard, Vancouver, ISO, and other styles

5

Ratcliff, Jeremy, Dung Nguyen, Matthew Fish, et al. "Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection." Journal of Infectious Diseases 224, no. 4 (2021): 595–605. http://dx.doi.org/10.1093/infdis/jiab283.

Full text

Abstract:

Abstract Background Convalescent plasma containing neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is under investigation for coronavirus disease 2019 (COVID-19) treatment. We report diverse virological characteristics of UK intensive care patients enrolled in the Immunoglobulin Domain of the REMAP-CAP randomized controlled trial that potentially influence treatment outcomes. Methods SARS-CoV-2 RNA in nasopharyngeal swabs collected pretreatment was quantified by PCR. Antibody status was determined by spike-protein ELISA. B.1.1.7 was differentiated from oth

APA, Harvard, Vancouver, ISO, and other styles

6

Harris, Gavin H., and Amesh A. Adalja. "Innovative approaches to COVID-19 medical countermeasure development." Journal of Antimicrobial Chemotherapy 78, Supplement_2 (2023): ii18—ii24. http://dx.doi.org/10.1093/jac/dkad312.

Full text

Abstract:

Abstract Background The COVID-19 pandemic, while unfortunately notable for immense strain and death throughout the world, has also shown great promise in the development of medical countermeasures. As the global scientific community shifted almost entirely towards vaccines, diagnostics and therapeutics, new trial designs most significantly adaptive platform trials, began to be used with greater speed and broader reach. These designs allowed for deploying and investigating new therapeutics, repurposing currently existing therapeutics and flexibly removing or adding additional medications as dat

APA, Harvard, Vancouver, ISO, and other styles

7

Ascierto, Paolo Antonio, Binqing Fu, and Haiming Wei. "IL-6 modulation for COVID-19: the right patients at the right time?" Journal for ImmunoTherapy of Cancer 9, no. 4 (2021): e002285. http://dx.doi.org/10.1136/jitc-2020-002285.

Full text

Abstract:

The ongoing pandemic caused by the novel coronavirus SARS-CoV-2 has disrupted the global economy and strained healthcare systems to their limits. After the virus first emerged in late 2019, the first intervention that demonstrated significant reductions in mortality for severe COVID-19 in large-scale trials was corticosteroids. Additional options that may reduce the burden on the healthcare system by reducing the number of patients requiring intensive care unit support are desperately needed, yet no therapy has conclusively established benefit in randomized studies for the management of modera

APA, Harvard, Vancouver, ISO, and other styles

8

Astorga González, Beatriz, and Niurka M. Dupotey Varela. "Protocolos de tratamiento a la COVID-19: aproximación desde una perspectiva farmacoterapéutica." Orange Journal 4, no. 7 (2022): 16–32. http://dx.doi.org/10.46502/issn.2710-995x/2022.7.02.

Full text

Abstract:

La introducción de los protocolos y guías de actuación clínica en los contextos sanitarios ha jugado un papel esencial en el combate a la COVID-19. Es por ello que el presente trabajo muestra los resultados derivados de una revisión narrativa realizada para describir el diseño e implementación de protocolos para el tratamiento a la COVID-19 en diferentes contextos sanitarios, desde el análisis de criterios farmacoterapéuticos. La metodología de Zillmer de 2018 fue utilizada, estableciéndose criterios para la inclusión de las publicaciones. De acuerdo con este criterio fueron identificadas 48 p

APA, Harvard, Vancouver, ISO, and other styles

9

Skvortsov, V. V., A. V. Tumarenko, E. A. Malyakina, and G. I. Maljakin. "Glucocorticoids in the combination therapy of COVID-19." Meditsinskiy sovet = Medical Council, no. 6 (May 4, 2023): 52–56. http://dx.doi.org/10.21518/ms2022-049.

Full text

Abstract:

Since the early months of the SARS-CoV-2 pandemic, the understanding that severe forms of COVID-19 are associated with systemic inflammation has spurred the medical community to greater efforts to evaluate the effect of numerous anti-inflammatory and immunomodulatory therapies. Corticosteroids have a broad and non-specific anti-inflammatory action; they can interfere with mRNA transcription of inflammatory cytokines, reducing the production of inflammatory mediators. Therefore, the use of glucocorticoids will reduce the complications caused by the cytokine storm. On the other hand, immunosuppr

APA, Harvard, Vancouver, ISO, and other styles

10

Lobastov, Kirill Victorovich, Evgeny Alekseevich Stepanov, Sergey Nikolaevich Tsaplin, et al. "Efficacy and safety of increased doses of anticoagulants in COVID-19 patients: a systematic review and meta-analysis." Hirurg (Surgeon), no. 01 (February 14, 2022): 50–65. http://dx.doi.org/10.33920/med-15-2201-05.

Full text

Abstract:

The aim of the study was to evaluate the efficacy and safety of increased doses of anticoagulants in comparison with standard doses in inpatients with COVID-19. Material and methods. A systematic review was carried out in October 2021 using the Pubmed database. The analysis included only randomized clinical trials with ≥200 participants that reported the death rate as the total number of cases or the percentage of patients. The primary outcome was all-cause mortality within the observation period. Additionally, the risk of arterial and venous thrombotic events, major and clinically relevant no

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!